HKEX: 2197
2026 Interim Report
Earlier from Clover Biopharmaceuticals
- Clover Announces Positive Phase 2 Clinical Data for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates in Older Adults
- Clover Announces Additional Positive U.S. Phase I Clinical Data for RSV Re-Vaccination in Older Adults
- Clover Initiates Phase 2 Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates
- Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances